Core Viewpoint - The retail pharmacy industry in China is entering a phase of negative growth by 2025, with a significant number of store closures and a shift in focus towards health services rather than just product sales [1][2][3] Group 1: Industry Growth and Challenges - The retail pharmacy sector has seen a 50% increase in store numbers over the past seven years, but the growth has reversed, with a net decrease of approximately 3,000 stores in the first quarter of 2025 [2][3] - The total market size for pharmaceuticals in China is projected to decline for the first time, with a forecast of 1.97 trillion yuan in 2024, reflecting a mere 0.9% growth in 2023 [2][3] - The median revenue growth for eight listed pharmacy companies is only 4.7%, while median profit has decreased by 32.9% year-on-year [2][3] Group 2: Market Dynamics and Strategic Responses - Many retail pharmacies are slowing down on new store openings, with a notable increase in the proportion of franchise stores to enhance market share [3] - The concentration of the top 100 retail chains has risen to 53%, indicating a trend towards consolidation in the industry [3] - The DTP (Direct to Patient) market is expanding, with a projected sales scale of 89.3 billion yuan in 2024, growing by 17.2% [4][5] Group 3: Opportunities for Innovation and Diversification - Despite declines in traditional categories like Chinese medicine and medical devices, the sales of biological products have surged by 17.7%, indicating a potential growth area for the industry [3][4] - There is a growing demand for personalized healthcare services, with over 85% of chronic disease patients expecting medication guidance and over 75% seeking disease awareness education [5][6] - Retail pharmacies are encouraged to explore partnerships with companies in beauty and health supplements, as well as to adopt a more diversified approach to meet evolving consumer needs [6][7]
关店潮来了！零售药店谋变
Zheng Quan Shi Bao Wang·2025-08-21 02:56